Cwm LLC Has $1.16 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CWM LLC lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 52.0% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 10,503 shares of the company's stock after selling 11,384 shares during the quarter. CWM LLC's holdings in Neurocrine Biosciences were worth $1,162,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Xponance Inc. lifted its holdings in Neurocrine Biosciences by 0.8% in the first quarter. Xponance Inc. now owns 27,282 shares of the company's stock valued at $3,017,000 after acquiring an additional 215 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Neurocrine Biosciences by 1,001.3% during the 1st quarter. Nisa Investment Advisors LLC now owns 14,042 shares of the company's stock valued at $1,553,000 after buying an additional 12,767 shares in the last quarter. Linden Thomas Advisory Services LLC grew its position in shares of Neurocrine Biosciences by 4.0% in the first quarter. Linden Thomas Advisory Services LLC now owns 6,603 shares of the company's stock valued at $730,000 after purchasing an additional 253 shares during the period. Blackhawk Capital Partners LLC. lifted its position in shares of Neurocrine Biosciences by 48.6% in the first quarter. Blackhawk Capital Partners LLC. now owns 14,521 shares of the company's stock valued at $1,606,000 after acquiring an additional 4,750 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its holdings in Neurocrine Biosciences by 3.8% in the 1st quarter. Crossmark Global Holdings Inc. now owns 8,785 shares of the company's stock valued at $972,000 after purchasing an additional 320 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Activity at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 457 shares of the stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the sale, the insider directly owned 4,730 shares of the company's stock, valued at $638,550. This represents a 8.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William H. Rastetter sold 30,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the transaction, the director owned 37,491 shares in the company, valued at approximately $4,131,508.20. The trade was a 44.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 120,251 shares of company stock valued at $14,978,602 over the last quarter. Corporate insiders own 4.30% of the company's stock.

Neurocrine Biosciences Price Performance

NBIX traded down $0.19 during trading on Monday, hitting $131.83. The company had a trading volume of 470,113 shares, compared to its average volume of 1,146,710. The company has a market cap of $13.05 billion, a PE ratio of 44.69, a P/E/G ratio of 1.35 and a beta of 0.24. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $157.98. The business has a 50-day moving average of $126.07 and a 200-day moving average of $121.21.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The company had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. During the same period in the prior year, the business earned $1.20 earnings per share. Neurocrine Biosciences's quarterly revenue was up 11.1% on a year-over-year basis. Research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on NBIX shares. UBS Group boosted their price target on shares of Neurocrine Biosciences from $152.00 to $174.00 and gave the company a "buy" rating in a research note on Wednesday, July 9th. JPMorgan Chase & Co. raised their target price on Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a report on Wednesday, March 26th. Wedbush reaffirmed an "outperform" rating on shares of Neurocrine Biosciences in a research report on Tuesday, May 6th. Royal Bank Of Canada reissued an "outperform" rating and issued a $145.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, June 2nd. Finally, BMO Capital Markets increased their target price on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $163.87.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.